We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Partnership Agreement to Provide Funding for Studies on Immunology of Cancer

By LabMedica International staff writers
Posted on 28 Feb 2016
A partnership agreement between a Germany-based pharmaceutical company and a major Israeli research institute will ensure several years' funding for studies in the fields of immunology and immuno-oncology.

The agreement between Merck KGaA (Darmstadt, Germany) and the Weizmann Institute of Science (Rehovot, Israel) confirms the German pharmaceutical company's commitment to the Israeli institute by providing the framework for provision of funds amounting to one million euros per year for each of the next three years. More...
The funds will be used to promote research in the fields of immunology and immuno-oncology over the initial three-year period with an option for multiple successive extensions of two years each.

Merck’s connection to the Weizmann Institute stretches as far back as 1978. Merck’s top selling multiple sclerosis drug Rebif, which had sales of 1.8 billion euros in 2014, has intellectual roots in the Weizmann Institute, as has its oncology drug Erbitux, which had sales of 900 million euros in 2014.

“We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immunology, and oncology as we are striving to deliver new solutions to respond to unmet medical needs,” said Stefan Oschmann, deputy CEO and vice chairman of the executive board of Merck KGaA. “We are excited that the new framework agreement will cover the first two of these three areas and are already looking forward to the proposals of the distinguished Weizmann scientists.”

“We are proud that such a fruitful relationship like the one we have with Merck has now been extended and that we have the chance to take part in creating new innovative solutions in such critical fields that so many patients globally are suffering from,” said Dr. Mudi Sheves, vice president of technology transfer at the Weizmann Institute of Science.

Related Links:

Merck KGaA
Weizmann Institute of Science




New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.